MARTINGALE-RISK
Martingale Risk, a specialist in global securities loss recovery, is originating a group action in the Netherlands against Philips on behalf of institutional investors, together with Grant & Eisenhofer as the Global Counsel and Old Haven Funding LLC as the Funder.
As reported by the U.S. regulator, the Food and Drug Administration (FDA), starting from at least October 2015, Philips was notified by customer complaints regarding its respiratory devices (sleep therapy devices used for the treatment of obstructive sleep apnea) causing potential health issues related to foam degradation. Upon receipt of this crucial information, Philips failed to proceed with any appropriate methods of risk analysis and to implement any corrective or preventive actions. Shareholders were not provided with any details regarding the severity of these matters nor the extent that Philips would be harmed financially, which in 2022 already resulted in €486 million in utilized provisions.
Following the June 14th, 2021 recall on millions of respiratory devices to address the health risks related to the foam, the FDA – that classified the recalls as Class I, the most serious type of recall – moved to swiftly investigate Philips, closing their investigation with several critical observations.
In response to an updated safety communication by the FDA, on Sept. 7th, 2023, Philips agreed to pay out at least $479 million to US consumers, as a means of managing and compensating for the health issues caused by its respiratory devices.
On April 4th, 2024, the FDA and the Department of Justice (DoJ) made a joint statement acknowledging Philips’ supposed failure to abide by the instructions and procedures of the remediation plan. This led to a recent Court-approved Consent Decree of Permanent Injunction (filed on April 9th, 2024), whereby Philips’ respiratory devices can no longer be manufactured or distributed from its US facilities, until they comply with various stringent reparative duties, as specified in the Recall Remediation Plan.
The finalization of the Consent Decree is undoubtedly a significant milestone for the protection of US-based consumers, yet action is still needed to further redress Philips’ misconduct, namely for institutional investors who purchased its equities, which were greatly impacted by Philips’ behavior. Martingale Risk, as the originator of the group action, will bring the proceedings in the Netherlands to recover its clients’ investment losses, which occurred throughout the period Nov. 2015-Nov. 2021.
Terms & Conditions:
Martingale Risk, together with Grant & Eisenhofer and Old Haven will be operating on a full contingent fee basis of the recovered amount as all legal, expert costs and expenses will be covered.
How to Proceed/Registration Deadline:
If your firm has invested or traded in Philips common stock and/or ADR from Oct. 30th, 2015-April 24th, 2023, please contact Mr. Marco Delzio (marco.delzio@martingalerisk.com) or Mr. Peter Ogden (peter.ogden@martingalerisk.com) for a free non-binding preliminary analysis.
The deadline to register for the proceedings is July 31st, 2024.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240522190127/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PHC and CCRM Collaborate to Develop Primary T-Cell Expansion Culture Processesto Enhance Efficiency and Improve Cell Quality10.2.2025 06:00:00 CET | Press release
PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture processes that will seek to accelerate the manufacturing of cell and gene therapy (CGT) products. This joint initiative will integrate “LiCellGrowTM(*2), PHC’s cell expansion system under development, with CCRM’s deep knowledge of regenerative medicine and biomanufacturing to establish new culture processes to improve cell culture efficiency and quality for CGTs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250209611769/en/ *For research purposes only. Anticipated visual image of LiCellGrow. All features subject to change. (Graphic: Business Wire) Primary T-cells are used in process development and manufacturing for CGTs, such as in CAR-T cell therapy.(*3) However, primary T-cells derived directly from patients often exhibit significant variability in growth rates and quality, ma
NTT DATA Unveils Global Insights on GenAI Adoption in Banking: Divergent Strategies for Boosting Productivity vs. Cutting Costs10.2.2025 05:00:00 CET | Press release
Research from NTT DATA finds that as GenAI adoption rises, new pressures on return of investment are at the forefront of the challenges facing the banking industry. NTT DATA, a global digital business and IT services leader, has today launched a new global research report uncovering the use of generative AI (GenAI) in the banking sector worldwide. The report, titled “Intelligent banking in the Age of AI,” has found that despite the growing adoption of GenAI technology in the banking industry, banks and financial institutions are split when it comes to outcome-based strategies – only half of banks (50%) see it as a tool for improving productivity and efficiency. Similarly, half (49%) believe it can be used for reducing operational IT spend. Transforming Banking Through GenAI GenAI is more disruptive than any previous advance in banking technology. It is less a question of if, but when banks embrace this technology, due to its transformative ability to embed intelligence at every layer o
Revolutionizing Air Compressor Operation: ELGi Unveils Ground-breaking “STABILISOR” Technology10.2.2025 04:30:00 CET | Press release
Setting New Standards in Compressed Air Reliability, Energy Costs, and Variable Flow In a significant leap forward for industrial air compression, Elgi Equipments (BSE: 522074; NSE: ELGIEQUIP), one of the world's leading air-compressor manufacturers with over 64 years of compressed air excellence, today announced the introduction of its pioneering compressed air stabilization technology. Designed to revolutionize the way compressors operate in plants with dynamic air demand, the STABILISOR system aims to address the longstanding challenges of unstable compressor performance, inefficiency, and excessive wear caused by frequent load/unload cycles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250204651563/en/ Patented Compressed Air Stabilization Technology (Graphic: Elgi Equipments) In industrial settings, the gap between compressor capacity and plant air demand is inherently dynamic. This variability leads to frequent cut-i
Andersen Global tilføjer større bredde til sit fodaftryk i Europa med Allyum i Belgien8.2.2025 14:17:00 CET | Pressemeddelelse
Andersen Global styrker sin platform i Europa gennem en samarbejdsaftale med Allyum, et førende Mergers & Acquisitions (M&A) firma i Belgien, hvilket betyder en endnu bredere skattemæssig og juridisk platform i regionen. Fra stiftelsen i 2004 har administrerende direktør Raphaël Abou, Allyum, specialiseret sig i omfattende finansielle tjenester til mid-cap virksomheder med et specifikt fokus på styring fra start til slut af transaktioner på salgssiden. Firmaet er eksperter inden for fusioner og opkøb, private investeringer, børsnoteringer, corporate venturing, aktionæromstrukturering samt finansiel analyse og planlægning. "I løbet af det seneste årti har vi hjulpet hundredvis af virksomheder med at foretage deres transaktioner og udviklet fremragende relationer med investeringsfondene i vores region," siger Raphaël. "Vores samarbejde med Andersen Global bliver en spændende mulighed for at anvende vores omfattende tilgang til finansiel rådgivning gennem den bedste globale platform." "Vi
Duravant to Acquire Pattyn, Provider of Packaging Automation Systems for Bulk and Industrial Applications7.2.2025 15:00:00 CET | Press release
Automation solutions leader Duravant has signed a definitive agreement to acquire Pattyn. Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has entered into a definitive agreement to acquire the Pattyn Group BV (‘Pattyn”), a designer and manufacturer of automation systems specializing in B2B packaging. Pattyn is recognized as the premier leader for delivering comprehensive automation solutions and value-added services for bag-in-box packaging applications. Headquartered in Bruges, Belgium, Pattyn has over 70 years of expertise in machinery design and turnkey systems for counting, weighing, filling, and packing technologies for food, ingredients, and various non-food sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207117623/en/ “We are extremely excited to partner with Pattyn,” said Mike
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom